Does switching from olaparib capsules to tablets increase toxicity in ovarian cancer patients?


In the latest Publication Perspective, published by the Video Journal of Biomedicine, lead study author of the recent Future Oncology article, Susana Banerjee (Institute of Cancer Research, London, UK) discusses the real-world study and the conclusion that switching from olaparib capsules to tablets in women with ovarian cancer is manageable, in terms of toxicity.

Abstract:

Aim: Describe rates of prespecified adverse events in patients who switched from olaparib capsules to tablets. Patients & methods: Retrospective, observational cohort analysis using self-controlled, pre–post design. Data on patients with ovarian cancer who switched from olaparib capsules to tablets between January 2015 and February 2019 were obtained from a US claims database. Results: Among all patients (n = 48), proportion with any prespecified adverse event was 45.8% (95% confidence interval: 31.4–60.8) during initial 90 days’ capsule use and 35.4% (22.2–50.5) during initial 90 days’ tablets use; difference -10.4% (-28.8–9.0). Conclusion: Switching from olaparib capsules to tablets was manageable with no evidence of increased toxicity. This real-world study supports the manageable tolerability of olaparib in women with ovarian cancer.

About the Video Journal of Biomedicine:

The Video Journal of Biomedicine, published by Future Medicine, provides the missing link between high-quality research information and its intended audience, be that fellow experts, researchers in other fields, students and trainees, or the general public (including patients and caregivers). Through concise, high-quality videos, with the author on screen or via voice-over animation, researchers are able to personally explain their work, highlighting its importance, placing it in context, and discussing future implications.

Visit the Video Journal of Biomedicine to find out more>>

The opinions expressed in this interview are those of the interviewee and do not necessarily reflect the views of Oncology Central or Future Science Group.